drugset / Trial / NCT00115297
Montelukast for Early Life Wheezing
Phase 2/3
Completed
62 enrolled
University of Massachusetts, Worcester
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
This study will determine the effects of montelukast on the duration of wheezing in children 12 months to 3 years of age who visit a physician for care of a wheezing illness. Only patients from the Ankara area of Hacettepe University Medical Center in Turkey will be included in this study.
Timeline
- Start
- 2004-09
- Primary completion
- 2016-10
- Completion
- 2016-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Montelukast | Other / unclassified | 4 mg | — |
| Subject | Montelukast | Other / unclassified | 5 mg | — |